Pembrolizumab (Anti-PD-1) and AMG386 (Angiopoietin-2 (Ang-2) in Patients With Advanced Solid Tumor
Phase 1 Completed
62 enrolled 17 charts
Study of CHS-388 (Formerly Known as SRF388) in Patients With Advanced Solid Tumors
Phase 1 Completed
145 enrolled
A Comparison of Methods for Assisting Needle Angle Selection During Image-guided Tissue Biopsy
Phase 1 Completed
17 enrolled
A Study of Autogene Cevumeran (RO7198457) as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Tumors
Phase 1 Completed
272 enrolled
SLM + Axitinib for Clear Cell RCC
Phase 1 Completed
46 enrolled
Preliminary Evaluation of Uptake of [68Ga]P16-093 in Metastatic Prostate and Renal Cancer
Phase 1 Completed
30 enrolled
Study of Continuous OSI-906 Dosing
Phase 1 Completed
95 enrolled
A Phase I Study of TAS-102 in Patients With Advanced Solid Tumors With Renal Impairment
Phase 1 Completed
43 enrolled
A Study of CDX-1140 (CD40) as Monotherapy or in Combination in Patients With Advanced Malignancies
Phase 1 Completed
132 enrolled
Neoadjuvant MEDI 4736 +/- Tremelimumab in Locally Advanced Renal Cell Carcinoma
Phase 1 Completed
29 enrolled
CPI-006 Alone and in Combination With Ciforadenant and With Pembrolizumab for Patients With Advanced Cancers
Phase 1 Completed
117 enrolled
OGX-011 and Docetaxel in Treating Patients With Metastatic or Locally Recurrent Solid Tumors
Phase 1 Completed
40 enrolled
A Study of JNJ-78306358 in Participants With Advanced Stage Solid Tumors
Phase 1 Completed
39 enrolled
Dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of QBS10072S
Phase 1 Completed
15 enrolled
Treatment of Patients With Advanced Renal Cancer With a Radiolabeled Antibody, Yttrium-90 Conjugated Chimeric G250
Phase 1 Completed
18 enrolled 15 charts
Safety Study With the Antibody, cG250, and Isotope, 124-Iodine, to Diagnose Patients With Renal Masses.
Phase 1 Completed
26 enrolled 11 charts
Cardiac Safety Study of Entinostat in Men and Women With Advanced Solid Tumors
Phase 1 Completed
30 enrolled
Study Of OX40 Agonist PF-04518600 Alone And In Combination With 4-1BB Agonist PF-05082566
Phase 1 Completed
174 enrolled 68 charts
JAVELIN Renal 100
Phase 1 Completed
55 enrolled 27 charts
177Lu-J591 Antibody in Patients With Nonprostate Metastatic Solid Tumors
Phase 1 Completed
20 enrolled
Phase I/Ib Study of NIS793 in Combination With PDR001 in Patients With Advanced Malignancies.
Phase 1 Completed
120 enrolled
Study of Everolimus (RAD001) in Combination With Lenalidomide
Phase 1 Completed
44 enrolled 9 charts
Continuation Study of Entinostat in Combination With Pembrolizumab in Patients With Advanced Solid Tumors
Phase 1 Completed
30 enrolled
Phase 1/1b Study to Evaluate the Safety and Tolerability of Ciforadenant Alone and in Combination With Atezolizumab in Advanced Cancers
Phase 1 Completed
502 enrolled
Study of Safety and Efficacy of Alpelisib With Everolimus or Alpelisib With Everolimus and Exemestane in Advanced Breast Cancer Patients, Renal Cell Cancer and Pancreatic Tumors
Phase 1 Completed
79 enrolled
Vaccine Therapy in Treating Patients With Advanced Kidney Cancer
Phase 1 Completed
14 enrolled
Study of Neoadjuvant Nivolumab in Patients With Non-metastatic Stage II-IV Clear Cell Renal Cell Carcinoma
Phase 1 Completed
17 enrolled
Bioequivalence & Food Effect Study in Patients With Solid Tumor or Hematologic Malignancies
Phase 1 Completed
89 enrolled
Study of Pre-operative Combination Therapy With Mogamulizumab and Nivolumab Against Solid Cancer Patients
Phase 1 Completed
16 enrolled
Sorafenib Tosylate and Hypoxia-Activated Prodrug TH-302 in Treating Patients With Advanced Kidney Cancer or Liver Cancer That Cannot Be Removed By Surgery
Phase 1 Completed
24 enrolled
Mechanism of Action of High-Dose IL-2 (Aldesleukin) in Metastatic Melanoma and Kidney Cancer
Phase 1 Completed
138 enrolled
Expanded Phase I Pazopanib and Everolimus in Advanced Solid Tumors and Previously Treated Advanced Urothelial Cancer
Phase 1 Completed
23 enrolled 16 charts
A Pharmacodynamic Study of Sirolimus and Metformin in Patients With Advanced Solid Tumors
Phase 1 Completed
24 enrolled
CTT1057, a Small Molecular Inhibitor of PSMA, as a Novel Imaging Agent of Neovascularization in Renal Cell Carcinoma
Phase 1 Completed
4 enrolled
A Phase 1, Dose Escalation Study of the Safety, Tolerability, and Pharmacokinetics of Intravenous Dimethane Sulfonate (DMS612) in Advanced Malignancies
Phase 1 Completed
60 enrolled
Vaccine Therapy in Treating Patients With Kidney Cancer
Phase 1 Completed
15 enrolled
Bortezomib and Cetuximab in Treating Patients With Advanced Solid Tumors
Phase 1 Completed
37 enrolled
Bortezomib and Gemcitabine in Treating Older Patients With Advanced Solid Tumors
Phase 1 Completed
17 enrolled
Irinotecan Plus Gemcitabine in Treating Patients With Unresectable or Metastatic Solid Tumors
Phase 1 Completed
38 enrolled
Study of Panobinostat in Combination With Sorafenib in Kidney, Soft Tissue or Lung Cancers
Phase 1 Completed
38 enrolled
Interleukin-2 With Sorafenib (BAY 43-9006) for Unresectable or Metastatic Clear Cell Renal Carcinoma (RCC) and Metastatic Melanoma
Phase 1 Completed
17 enrolled
Effects of STM 434 Alone or in Combination With Liposomal Doxorubicin in Patients With Ovarian Cancer or Other Advanced Solid Tumors
Phase 1 Completed
32 enrolled
Bevacizumab and BKM-120 in Patients With Metastatic Renal Cell Carcinoma
Phase 1 Completed
32 enrolled
AMG 172 First in Human Study in Patients With Kidney Cancer
Phase 1 Completed
37 enrolled
PTK/RAD
Phase 1 Completed
37 enrolled
Percutaneous Renal Tumor Cryoablation Followed by Biopsy
Phase 1 Completed
17 enrolled
Spectroscopy With Surface Coils and Decoupling
Phase 1 Completed
582 enrolled
Pilot Evaluation of 124I-Iodo-Azomycin Galacto-Pyranoside (*IAZGP) Positron Emission Tomography (PET) in the Imaging of Hypoxic Tumors
Phase 1 Completed
15 enrolled
Interleukin-2 Plus Bryostatin 1 in Treating Patients With Melanoma or Kidney Cancer
Phase 1 Completed
17 enrolled
Sunitinib Plus Temsirolimus in Patients With Renal Cell Cancer (RCC)
Phase 1 Completed
23 enrolled